References
- Awdishu, L., A. Atilano-Roque, S. Tuey, and M. S. Joy. 2020. Identification of novel biomarkers for predicting kidney injury due to drugs using “Omic” strategies. Pharmgenomics Pers. Med. 13:687–705. doi:https://doi.org/10.2147/PGPM.S239471.
- Beger, R. D., J. Sun, and L. K. Schnackenberg. 2010. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243 (2):154–66. doi:https://doi.org/10.1016/j.taap.2009.11.019.
- Bennett, W. M. 1997. Drug nephrotoxicity: An overview. Ren. Fail. 19 (2):221–24. doi:https://doi.org/10.3109/08860229709026280.
- Bonvallot, N., M. Tremblay-Franco, C. Chevrier, C. Canlet, L. Debrauwer, J. P. Cravedi, and S. Cordier. 2014. Potential input from metabolomics for exploring and understanding the links between environment and health. J. Toxicol. Environ. Health B 17 (1):21–44. doi:https://doi.org/10.1080/10937404.2013.860318.
- Cheon, J. H., S. Y. Kim, J. Y. Son, Y. R. Kang, J. H. An, J. H. Kwon, H. S. Song, A. Moon, B. M. Lee, and H. S. Kim. 2016. Pyruvate kinase M2: A novel biomarker for the early detection of acute kidney injury. Toxicol. Res. 32 (1):47–56. doi:https://doi.org/10.5487/TR.2016.32.1.047.
- Choi, Y. M., H. K. Kim, W. Shim, M. A. Anwer, J. W. Kwon, H. K. Kwon, H. J. Kim, H. Jeong, H. M. Kim, D. Hwang, et al. 2015. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One 10 (8):e0135083. doi:https://doi.org/10.1371/journal.pone.0135083.
- Choudhury, D., and Z. Ahmed. 2006. Drug-associated renal dysfunction and injury. Nat. Clin. Pract. Nephrol 2 (2):80–91. doi:https://doi.org/10.1038/ncpneph0076.
- Ciarimboli, G., T. Ludwig, D. Lang, H. Pavenstädt, H. Koepsell, H. J. Piechota, J. Haier, U. Jaehde, J. Zisowsky, and E. Schlatter. 2005. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167 (6):1477–84. doi:https://doi.org/10.1016/S0002-9440(10)61234-5.
- Côté, J. M., P. T. Murray, and M. H. Rosner. 2020. New drugs for acute kidney injury. Curr. Opin. Crit. Care 26 (6):525–35. doi:https://doi.org/10.1097/MCC.0000000000000778.
- Cummings, B. S., and R. G. Schnellmann. 2002. Cisplatin-induced renal cell apoptosis: Caspase 3-dependent and -independent pathways. J. Pharmacol. Exp. Ther. 302 (1):8–17. doi:https://doi.org/10.1124/jpet.302.1.8.
- Dasari, S., and P. B. Tchounwou. 2014. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 740:364–78. doi:https://doi.org/10.1016/j.ejphar.2014.07.025.
- Dixit, M., T. Doan, R. Kirschner, and N. Dixit. 2010. Significant acute kidney injury due to non-steroidal anti-inflammatory drugs: Inpatient setting. Pharmaceuticals 3 (4):1279–85. doi:https://doi.org/10.3390/ph3041279.
- Doke, S. K., and S. C. Dhawale. 2015. Alternatives to animal testing: A review. Saudi. Pharm. J. 23 (3):223–29. doi:https://doi.org/10.1016/j.jsps.2013.11.002.
- Dos Santos, R. P., A. R. S. Carvalho, L. A. B. Peres, C. Ronco, and E. Macedo. 2019. An epidemiologic overview of acute kidney injury in intensive care units. Rev. Assoc. Med. Bras. 65 (8):1094–101. doi:https://doi.org/10.1590/1806-9282.65.8.1094.
- Dowling, P., and M. Clynes. 2011. Conditioned media from cell lines: A complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics 11 (4):794–804. doi:https://doi.org/10.1002/pmic.201000530.
- Efeyan, A., and M. Serrano. 2007. p53: Guardian of the genome and policeman of the oncogenes. Cell Cycle 6 (9):1006–10. doi:https://doi.org/10.4161/cc.6.9.4211.
- Espandiari, P., B. Rosenzweig, J. Zhang, Y. Zhou, L. Schnackenberg, V. S. Vaidya, P. L. Goering, R. P. Brown, J. V. Bonventre, K. Mahjoob, et al. 2010. Age-related differences in susceptibility to cisplatin-induced renal toxicity. J. Appl. Toxicol. 30 (2):172–82. doi:https://doi.org/10.1002/jat.1484.
- Evans, D. B. 1980. Drugs and the kidney. Br. J. Hosp. Med. 24 (3): 244, 246–47, 249–51.
- Ferguson, M. A., V. S. Vaidya, and J. V. Bonventre. 2008. Biomarkers of nephrotoxic acute kidney injury. Toxicology 245 (3):182–93. doi:https://doi.org/10.1016/j.tox.2007.12.024.
- Goldstein, S. L. 2016. Medication-induced acute kidney injury. Curr. Opin. Crit. Care 22 (6):542–45. doi:https://doi.org/10.1097/MCC.0000000000000355.
- Griffin, B. R., S. Faubel, and C. L. Edelstein. 2019. Biomarkers of drug-Induced kidney toxicity. Ther. Drug Monit. 41 (2):213–26. doi:https://doi.org/10.1097/FTD.0000000000000589.
- Hallows, W. C., S. Lee, and J. M. Denu. 2006. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. U. S. A. 103 (27):10230–35. doi:https://doi.org/10.1073/pnas.0604392103.
- Hamroun, A., R. Lenain, J. J. Bigna, E. Speyer, L. Bui, P. Chamley, N. Pottier, C. Cauffiez, E. Dewaeles, X. Dhalluin, et al. 2019. Prevention of cisplatin-induced acute kidney injury: A systematic review and meta-analysis. Drugs 79 (14):1567–82. doi:https://doi.org/10.1007/s40265-019-01182-1.
- Hanigan, M. H., and P. Devarajan. 2003. Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Ther 1:47–61.
- Holditch, S. J., C. N. Brown, A. M. Lombardi, K. N. Nguyen, and C. L. Edelstein. 2019. Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int. J. Mol. Sci. 20 (12):3011. doi:https://doi.org/10.3390/ijms20123011.
- Huang, J. X., G. Kaeslin, M. V. Ranall, M. A. Blaskovich, B. Becker, M. S. Butler, M. H. Little, L. H. Lash, and M. A. Cooper. 2015. Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: Comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells. Pharmacol. Res. Perspect 3 (3):e00148. doi:https://doi.org/10.1002/prp2.148.
- Jiang, M., and Z. Dong. 2008. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J. Pharmacol. Exp. Ther. 327 (2):300–07. doi:https://doi.org/10.1124/jpet.108.139162.
- Jiang, M., X. Yi, S. Hsu, C. Y. Wang, and Z. Dong. 2004. Role of p53 in cisplatin-induced tubular cell apoptosis: Dependence on p53 transcriptional activity. Am. J. Physiol. Renal Physiol. 287 (6):F1140–F1147. doi:https://doi.org/10.1152/ajprenal.00262.2004.
- Kim, J. S., J. Y. Son, K. S. Kim, H. J. Lim, M. Y. Ahn, S. J. Kwack, Y. M. Kim, K. Y. Lee, J. Lee, B. M. Lee, et al. 2018. Hepatic damage exacerbates cisplatin-induced acute kidney injury in Sprague-Dawley rats. J. Toxicol. Environ. Health A 81 (11):397–407. doi:https://doi.org/10.1080/15287394.2018.1451179.
- Kim, K. S., H. Y. Yang, H. S. Song, Y. P. Kang, J. H. Kwon, J. H. An, J. Y. Son, S. J. Kwack, Y. M. Kim, O. N. Bae, et al. 2017. Identification of a sensitive urinary biomarker, selenium-binding protein 1, for early detection of acute kidney injury. J. Toxicol. Environ. Health A 80 (9):453–64. doi:https://doi.org/10.1080/15287394.2017.1299655.
- Kim, M. K., K. B. Kim, H. S. Kim, and B. M. Lee. 2019. Alternative skin sensitization prediction and risk assessment using proinflammatory biomarkers, interleukin-1 beta (IL-1β) and inducible nitric oxide synthase (iNOS). J. Toxicol. Environ. Health A 82 (5):361–78. doi:https://doi.org/10.1080/15287394.2019.1609183.
- Kim, S. Y., H. M. Lee, K. S. Kim, H. S. Kim, and A. Moon. 2015. Noninvasive biomarker candidates for cadmium-induced nephrotoxicity by 2DE/MALDI-TOF-MS and SILAC/LC-MS proteomic analyses. Toxicol. Sci 148 (1):167–82. doi:https://doi.org/10.1093/toxsci/kfv172.
- Kim, S. Y., and A. Moon. 2012. Drug-induced nephrotoxicity and its biomarkers. Biomol. Ther. 20 (3):268–72. doi:https://doi.org/10.4062/biomolther.2012.20.3.268.
- Kim, S. Y., S. J. Sohn, A. J. Won, H. S. Kim, and A. Moon. 2014. Identification of noninvasive biomarkers for nephrotoxicity using HK-2 human kidney epithelial cells. Toxicol. Sci 140 (2):247–58. doi:https://doi.org/10.1093/toxsci/kfu096.
- Kim, T. H., M. Y. Ahn, H. J. Lim, Y. J. Lee, Y. J. Shin, U. De, J. Lee, B. M. Lee, S. Kim, and H. S. Kim. 2012. Evaluation of metabolomic profiling against renal toxicity in Sprague-Dawley rats treated with melamine and cyanuric acid. Arch. Toxicol 86 (12):1885–97. doi:https://doi.org/10.1007/s00204-012-0910-7.
- Lee, E. K., Y. J. Shin, E. Y. Park, N. D. Kim, A. Moon, S. J. Kwack, J. Y. Son, S. Kacew, B. M. Lee, O. N. Bae, et al. 2017. Selenium-binding protein 1: A sensitive urinary biomarker to detect heavy metal-induced nephrotoxicity. Arch. Toxicol 91 (4):1635–48. doi:https://doi.org/10.1007/s00204-016-1832-6.
- Lee, J. D., H. Y. Kim, J. J. Park, S. B. Oh, H. Goo, K. J. Cho, S. Kim, and K. B. Kim. 2021. Metabolomics approach to biomarkers of dry eye disease using 1H-NMR in rats. J. Toxicol. Environ. Health A 84 (8):313–30. doi:https://doi.org/10.1080/15287394.2020.1867274.
- Lee, J. T., and W. Gu. 2013. SIRT1: Regulator of p53 deacetylation. Genes Cancer 4 (3–4):112–17. doi:https://doi.org/10.1177/1947601913484496.
- Lee, Y. K., E. Y. Park, S. Kim, J. Y. Son, T. H. Kim, W. G. Kang, T. C. Jeong, K. B. Kim, S. J. Kwack, J. Lee, et al. 2014. Evaluation of cadmium-induced nephrotoxicity using urinary metabolomic profiles in Sprague-Dawley male rats. J. Toxicol. Environ. Health A 77 (22–24):1384–98. doi:https://doi.org/10.1080/15287394.2014.951755.
- Li, C., N. Xie, Y. Li, C. Liu, F. F. Hou, and J. Wang. 2019. N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation. Free Radic. Biol. Med. 130:512–27. doi:https://doi.org/10.1016/j.freeradbiomed.2018.11.006.
- Liu, X., D. E. Cooper, A. A. Cluntun, M. O. Warmoes, S. Zhao, M. A. Reid, J. Liu, P. J. Lund, M. Lopes, B. A. Garcia, et al. 2018. Acetate production from glucose and coupling to mitochondrial metabolism in mammals. Cell 175 (2):502–13. doi:https://doi.org/10.1016/j.cell.2018.08.040.
- Małyszko, J., K. Kozłowska, L. Kozłowski, and J. Małyszko. 2016. Nephrotoxicity of anticancer treatment. Nephrol. Dial. Transplant. 32 (6):924–36. doi:https://doi.org/10.1093/ndt/gfw338.
- Manohar, S., and N. Leung. 2018. Cisplatin nephrotoxicity: A review of the literature. J. Nephrol 31 (1):15–25. doi:https://doi.org/10.1007/s40620-017-0392-z.
- McKay, B. C., C. Becerril, and M. Ljungman. 2001. P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 20 (46):6805–08. doi:https://doi.org/10.1038/sj.onc.1204901.
- Michan, S., and D. Sinclair. 2007. Sirtuins in mammals: Insights into their biological function. Biochem. J. 404 (1):1–13. doi:https://doi.org/10.1042/BJ20070140.
- Miller, R. P., R. K. Tadagavadi, G. Ramesh, and W. B. Reeves. 2010. Mechanisms of cisplatin nephrotoxicity. Toxins 2 (11):2490–518. doi:https://doi.org/10.3390/toxins2112490.
- Moran, S. M., and B. D. Myers. 1985. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int. 27 (6):928–37. doi:https://doi.org/10.1038/ki.1985.101.
- Olivares, D., J. Perez-Hernandez, M. J. Forner, C. Perez-Soriano, M. C. Tormos, G. T. Saez, F. J. Chaves, J. Redon, and R. Cortes. 2018. Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis. Clin. Sci. 132 (5):569–79. doi:https://doi.org/10.1042/CS20171410.
- Ong, A. L. C., and T. S. Ramasamy. 2018. Role of sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res. Rev. 43:64–80. doi:https://doi.org/10.1016/j.arr.2018.02.004.
- Pabla, N., and Z. Dong. 2008. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73 (9):994–1007. doi:https://doi.org/10.1038/sj.ki.5002786.
- Pabla, N., S. Huang, Q. S. Mi, R. Daniel, and Z. Dong. 2008. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J. Biol. Chem. 283 (10):6572–83. doi:https://doi.org/10.1074/jbc.M707568200.
- Perazella, M. A. 2019. Drug-induced acute kidney injury: Diverse mechanisms of tubular injury. Curr. Opin. Crit. Care 25 (6):550–57. doi:https://doi.org/10.1097/MCC.0000000000000653.
- Qin, W., W. Xie, X. Yang, N. Xia, and K. Yang. 2016. Inhibiting microRNA-449 attenuates cisplatin-induced injury in NRK-52E cells possibly via regulating the SIRT1/p53/BAX pathway. Med. Sci. Monit. 22:818–23. doi:https://doi.org/10.12659/MSM.897187.
- Rahman, S., and R. Islam. 2011. Mammalian Sirt1: Insights on its biological functions. Cell Commun. Signal. 9 (1):11. doi:https://doi.org/10.1186/1478-811X-9-11.
- Raj, N., and L. D. Attardi. 2017. The transactivation domains of the p53 protein. Cold Spring Harb. Perspect. Med. 7 (1):a026047. doi:https://doi.org/10.1101/cshperspect.a026047.
- Ryu, S. H., J. D. Lee, J. W. Kim, S. Kim, S. Kim, and K. B. Kim. 2019. 1H NMR toxicometabolomics following cisplatin-induced nephrotoxicity in male rats. J. Toxicol. Sci. 44 (1):57–71. doi:https://doi.org/10.2131/jts.44.57.
- Safirstein, R., J. Winston, M. Goldstein, D. Moel, S. Dikman, and J. Guttenplan. 1986. Cisplatin nephrotoxicity. Am. J. Kidney Dis. 8 (5):356–67. doi:https://doi.org/10.1016/S0272-6386(86)80111-1.
- Schlattner, U., M. Tokarska-Schlattner, and T. Wallimann. 2006. Mitochondrial creatine kinase in human health and disease. Biochim. Biophys. Acta. 1762 (2):164–80. doi:https://doi.org/10.1016/j.bbadis.2005.09.004.
- Sohn, S. J., S. Y. Kim, H. S. Kim, Y. J. Chun, S. Y. Han, S. H. Kim, and A. Moon. 2013. In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells. Toxicol. Lett 217 (3):235–42. doi:https://doi.org/10.1016/j.toxlet.2012.12.015.
- Star, R. A. 1998. Treatment of acute renal failure. Kidney Int. 54 (6):1817–31. doi:https://doi.org/10.1046/j.1523-1755.1998.00210.x.
- Taber, S. S., and B. A. Mueller. 2006. Drug-associated renal dysfunction. Crit. Care Clin 22 (2):357–74. doi:https://doi.org/10.1016/j.ccc.2006.02.003.
- Thukral, S. K., P. J. Nordone, R. Hu, L. Sullivan, E. Galambos, V. D. Fitzpatrick, L. Healy, M. B. Bass, M. E. Cosenza, and C. A. Afshari. 2005. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 33 (3):343–55. doi:https://doi.org/10.1080/01926230590927230.
- Tiong, H. Y., P. Huang, S. Xiong, Y. Li, A. Vathsala, and D. Zink. 2014. Drug-Induced Nephrotoxicity: Clinical Impact and Preclinical in vitro Models. Mol. Pharm. 11 (7):1933–48. doi:https://doi.org/10.1021/mp400720w.
- Vasconcelos, A. L., M. J. Silva, and H. Louro. 2019. In vitro exposure to the next-generation plasticizer diisononyl cyclohexane-1,2-dicarboxylate (DINCH): Cytotoxicity and genotoxicity assessment in human cells. J. Toxicol. Environ. Health A 82 (9):526–36. doi:https://doi.org/10.1080/15287394.2019.1634376.
- Vervaet, B. A., P. C. D’Haese, and A. Verhulst. 2017. Environmental toxin-induced acute kidney injury. Clin. Kidney J. 10 (6):747–58. doi:https://doi.org/10.1093/ckj/sfx062.
- Viant, M. R., T. M. D. Ebbels, R. D. Beger, D. R. Ekman, D. J. T. Epps, H. Kamp, P. E. G. Leonards, G. D. Loizou, J. I. MacRae, B. Van Ravenzwaay, et al. 2019. Use cases, best practice and reporting standards for metabolomics in regulatory toxicology. Nat. Commun. 10 (1):3041. doi:https://doi.org/10.1038/s41467-019-10900-y.
- Vinken, P., S. Starckx, E. Barale-Thomas, A. Looszova, M. Sonee, N. Goeminne, L. Versmissen, K. Buyens, and A. Lampo. 2012. Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicol. Pathol. 40 (7):1049–62. doi:https://doi.org/10.1177/0192623312444765.
- Waller, D. G. 2007. Drugs and the kidney: More than a question of dose. Br. J. Clin. Pharmacol. 64 (6):719–21. doi:https://doi.org/10.1111/j.1365-2125.2007.03073.x.
- Won, A. J., S. Kim, Y. G. Kim, K. B. Kim, W. S. Choi, S. Kacew, K. S. Kim, J. H. Jung, B. M. Lee, S. Kim, et al. 2016. Discovery of urinary metabolomic biomarkers for early detection of acute kidney injury. Mol. Biosyst. 12 (1):133–44. doi:https://doi.org/10.1039/C5MB00492F.
- Wu, H., and J. Huang. 2018. Drug-induced nephrotoxicity: Pathogenic mechanisms, biomarkers and prevention strategies. Curr. Drug Metab 19 (7):559–67. doi:https://doi.org/10.2174/1389200218666171108154419.
- Yang, X., M. Fraser, U. M. Moll, A. Basak, and B. K. Tsang. 2006. Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res. 66 (6):3126–36. doi:https://doi.org/10.1158/0008-5472.CAN-05-0425.
- Ympa, Y. P., Y. Sakr, K. Reinhart, and J. L. Vincent. 2005. Has mortality from acute renal failure decreased? A systematic review of the literature. Am. J. Med. 118 (8):827–32. doi:https://doi.org/10.1016/j.amjmed.2005.01.069.
- Zhang, A., H. Sun, G. Yan, P. Wang, and X. Wang. 2015. Metabolomics for biomarker discovery: Moving to the clinic. Biomed. Res. Int. 2015:354671.
- Zhou, Y., V. S. Vaidya, R. P. Brown, J. Zhang, B. A. Rosenzweig, K. L. Thompson, T. J. Miller, J. V. Bonventre, and P. L. Goering. 2008. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol. Sci 101 (1):159–70. doi:https://doi.org/10.1093/toxsci/kfm260.